v3.26.3
Segment Information - Schedule of Segment Net Loss and Reconciliations of Segment Operating Loss to Loss Before Income Tax Benefit (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Revenue $ 18,552 $ 5,175 $ 32,694 $ 39,143
General and administrative 32,561 41,628 108,684 142,932
Depreciation and amortization     54,375 64,223
Significant segment expenses        
Loss from operations (123,176) (172,202) (386,648) (539,798)
Other non-operating income, net 4,165 9,952 14,524 3,005
Income tax benefit (expense) (25) (3) 4,579 156
Net loss (119,036) (162,253) (367,545) (536,637)
Reportable Segment        
Segment Reporting [Line Items]        
Revenue 18,552 5,175 32,694 39,143
Clinical programs 23,939 20,212 61,135 56,798
Internal & partnered discovery 32,947 50,351 98,834 122,006
Platform technology & infrastructure 20,517 24,285 60,060 86,277
General and administrative 20,783 37,107 75,450 116,135
Depreciation and amortization 16,535 21,043 54,375 64,223
Stock based compensation 23,028 25,244 64,741 87,460
Data records 5,798 0 8,860 49,859
UK R&D tax credit & other (1,819) (865) (4,113) (3,817)
Significant segment expenses        
Loss from operations (123,176) (172,202) (386,648) (539,798)
Other non-operating income, net 4,165 9,952 14,524 3,005
Income tax benefit (expense) (25) (3) 4,579 156
Net loss (119,036) (162,253) (367,545) (536,637)
Supplemental asset information        
Total expenditures for additions to long-lived assets $ 1,076 $ 39 $ 1,378 $ 5,283